ArticleNPJ digital medicine2026
Digital decision support using a phospholipid-dependent biomarker for early exclusion of negative cases in lupus anticoagulant diagnostics.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus anticoagulant (LAC) testing is central to antiphospholipid syndrome diagnostics and thrombotic risk assessment, but guideline-based workflows can be operationally complex, resource-intensive, and highly imbalanced. In our real-world cohort, completed LAC evaluations required an average of approximately 7 downstream clot-based assays, while nearly 90% of final classifications were negative. We developed and evaluated MINI-LAC™ (Minimal Lupus Anticoagulant), a biologically grounded digital decision-support framework designed for early exclusion of cases highly likely to yield negative final LAC classifications using routinely available pre-LAC coagulation parameters. Across 7454 LAC evaluations from a tertiary medical center, the phospholipid-poor versus phospholipid-rich activated partial thromboplastin time ratio (PTT-FSL/PTT-FS) demonstrated strong discrimination across LAC outcome categories (p < 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.